Cabozantinib malate is a malate salt that is the mono-(S)-malate salt of cabozantinib. A multi-tyrosine kinase inhibitor, used for the treatment of progressive, metastatic, medullary thyroid cancer. Among its listed roles, it functions as a tyrosine kinase inhibitor, an antineoplastic agent and a prodrug. It includes a cabozantinib. It is grouped under the following drug class(es): Antineoplastic agents and Tyrosine Kinase Inhibitors. Its therapeutic use is listed as antineoplastics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Cabozantinib L-Malate, Cabometyx and Cometriq. Its PubChem CID is 25102846.
Cabozantinib s-malate
| CAS No | 1140909-48-3 |
|---|---|
| Molecular Formula | C32H30FN3O10 |
| Molecular Weight | 635.6 g/mol |
| Synonyms | 1-N-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-N‘-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;(2S)-2-hydroxybutanedioic acid |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Cabozantinib malate is a malate salt that is the mono-(S)-malate salt of cabozantinib. A multi-tyrosine kinase inhibitor, used for the treatment of progressive, metastatic, medullary thyroid cancer.
The listed CAS number is 1140909-48-3.
The listed molecular formula is C32H30FN3O10.
The listed molecular weight is 635.6 g/mol.
1-N-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-N‘-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;(2S)-2-hydroxybutanedioic acid.
The source lists Cabozantinib L-Malate, Cabometyx and Cometriq.